Moderna (MRNA) Net Income (2017 - 2026)
Moderna (MRNA) posted quarterly Net Income of -$782.0 million for Q2 2026, up 5.21% year-over-year from -$743.3 million in Q2 2025, and up 41.77% on a QoQ basis from -$1.3 billion in Q1 2026.
Moderna (MRNA) Net Income (2017 - 2026) Analysis & Trends
Moderna has reported Net Income for 10 years, with the latest figure at -$782.0 million in Q2 2026.
- Net Income for Q2 2026 came in at -$782.0 million, up 5.21% year-over-year; the trailing twelve-month figure through Jun 2026 was -$3.2 billion (down 8.54% YoY), and the FY2025 annual result was -$2.8 billion, up 20.75% from the prior year.
- Net Income climbed to -$782.0 million in Q2 2026, from -$1.3 billion in the prior quarter.
- Over five years, Net Income peaked at $3.7 billion in Q1 2022 and troughed at -$3.6 billion in Q3 2023.
- A 5-year average of -$270.0 million and a median of -$803.5 million in 2025 frame the typical range for Net Income.
- The widest annual swing landed in 2022, when Net Income jumped 199.51%; it then plunged 1638.46% in 2025.
- A 5-year view of Net Income shows it stood at $1.5 billion in 2022, then tumbled by 85.19% to $217.0 million in 2023, then sank by 616.13% to -$1.1 billion in 2024, then advanced by 26.25% to -$826.0 million in 2025, then advanced by 5.33% to -$782.0 million in 2026.
- Per Business Quant data, the three most recent Net Income figures were -$782.0 million in Q2 2026, -$1.3 billion in Q1 2026, and -$826.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn | -782.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -782.00 Mn |
| Mar 31, 2026 | -1.34 Bn |
| Dec 31, 2025 | -826.00 Mn |
| Sep 30, 2025 | -200.00 Mn |
| Jun 30, 2025 | -825.00 Mn |
| Mar 31, 2025 | -971.00 Mn |
| Dec 31, 2024 | -1.12 Bn |
| Sep 30, 2024 | 13.00 Mn |
| Jun 30, 2024 | -1.28 Bn |
| Mar 31, 2024 | -1.18 Bn |
| Dec 31, 2023 | 217.00 Mn |
| Sep 30, 2023 | -3.63 Bn |
| Jun 30, 2023 | -1.38 Bn |
| Mar 31, 2023 | 79.00 Mn |
| Dec 31, 2022 | 1.47 Bn |
| Sep 30, 2022 | 1.04 Bn |
| Jun 30, 2022 | 2.20 Bn |
| Mar 31, 2022 | 3.66 Bn |
| Dec 31, 2021 | 4.87 Bn |
| Sep 30, 2021 | 3.33 Bn |